Japan Stock of the Day – Nov 19, 2026: CanBas <4575>
Thursday, November 19, 2026
On November 19, 2026, the most talked-about Japanese stock online was CanBas <4575>.
Background: Shortly after noon on the 19th, drug discovery venture CanBas (Growth Market) announced that it had received approval from the European Medicines Agency (EMA) to start a Phase 3 clinical trial of its anticancer candidate CBP501, an "immune igniter," in third-line treatment of pancreatic cancer. The pivotal trial, aimed at new drug approval, will compare a three-drug combination of CBP501, cisplatin and nivolumab with existing regimens chosen by physicians. The plan covers about 180 patients at around 50 sites in eight countries, and contracts have already been signed with about half of the sites. The company switched the main line of its development to Europe in 2024 and had been awaiting approval. Buy orders flooded in during the afternoon session after the announcement, and the stock closed at its daily limit (limit-up) of 774 yen, up 100 yen (14.8%). Its market capitalization is about 15.3 billion yen. The company expects the trial to finish in the first half of 2029.
CanBas (4575)
Latest close (11/19): ¥774 (+100, +14.84%)
Written by Kabutaro, an individual investor in Japanese stocks since 2007 (profile in Japanese).